Abstract
Thiotepa is an alkylating agent that was first synthesised in the 1950s. It can be administered intravenously, intravesically and intrathecally. At conventional doses the main adverse effect is haematopoietic toxicity. For about 10 years now thiotepa has been used at high doses prior to bone marrow transplantation. High-dose thiotepa has been particularly developed in the USA, while high-dose melphalan is preferred in Europe.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ayash U, Elias A, Wheeler C et al: Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994 12: 37–44
Cohen BE, Egorin MJ, Kohlhepp EA, Aisner J, Gutierrez PL: Human pharmacokinetics and urinary excretion of thiotepa and its metabolites. Cancer Treat Rep 1986 70: 859–864
Egorin MJ, Snyder SW, Pan S, Daly C: Cellular transport and accumulation of thiotepa. Semin Oncol 1990 17 suppl 3: 7–17
Finlay JL, August C, Packer R et al: High-dose multiagent chemotherapy followed by bone marrow rescue for malignant astrocytomas of childhood and adolescence. J Neurol Oncol 1990 9: 239–248
Heidemann RL, Cole DE, Balis F: Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 1989 49: 736–741
Henner WD, Shea TC, Furlong EA et al: Pharmacokinetics of continuous infusion of high-dose thiothepa. Cancer Treat Rep 1987 71: 1043–1047
Kalifa C, Hartmann O, Demeocq F et al: High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase Il study. Bone Marrow Transplant 1992 9: 227–233
Lazarus HM, Reed MC, Spitzer TR, Rabas MS, Blu-mer JL: High-dose in thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep 1987 71: 689–695
O’Dwyer PJ, La Creta F, Engstrom PF: Phase I/ pharmacokinetic reevaluation of thiotepa. Cancer Res 1991 51: 3171–3176
Przepiorka D, Ippoliti C, Giralt S et al: A phase II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation. Bone Marrow Transplant 1994 14: 449–453
Teicher BA, Holden SA, Eder JP, Herman S, Antman K, Frei Ill E: Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol 1990 17 suppl 3: 18–32
Wolff SN, Herzig RH, Fay JW: High-dose N,N’,N“triethylenethiophosphoramide thiotepa with autologous bone marrow transplantation: phase I studies. Sem Oncol 1990 17 suppl 3: 2–6
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Vassal, G., Hartmann, O. (1998). Pharmacotoxicology of High-Dose Thiotepa. In: Aapro, M.S., Maraninchi, D. (eds) The Role of Multiple Intensification in Medical Oncology. ESO European School of Oncology Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-01156-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-662-01156-0_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-01158-4
Online ISBN: 978-3-662-01156-0
eBook Packages: Springer Book Archive